Abstract:Attention-deficit-hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that impairs social, academic, and occupational functioning in children, adolescents, and adults. In patients with ADHD, neurobiologic research has shown a lack of connectivity in key brain regions, inhibitory control deficits, delayed brain maturation, and noradrenergic and dopaminergic dysfunction in multiple brain regions. The prevalence of this disorder in the United States is 6-9% in youth (i.e., children and adolescents) and 3-5% in adults. Prevalence rates for youth are similar worldwide. Children with ADHD are at greater risk than children without ADHD for substance abuse and delinquency whether or not they receive drug therapy; however, early treatment with psychoeducation as well as drug therapy and/or behavioral intervention may decrease negative outcomes of ADHD, including the rate of conduct disorder and adult antisocial personality disorder. Drug therapy is effective for all age groups, even preschoolers, and for late-onset ADHD in adults. Stimulants, such as methylphenidate and amphetamine, are the most effective therapy and have a good safety profile; although recent concerns of sudden unexplained death, psychiatric adverse effects, and growth effects have prompted the introduction of other therapies. Atomoxetine, a nonstimulant, has no abuse potential, causes less insomnia than stimulants, and poses minimal risk of growth effects. Other drug options include clonidine and guanfacine, but both can cause bradycardia and sedation. Polyunsaturated fatty acids (fish oil), acetyl-L-carnitine, and iron supplements (for youth with low ferritin levels) show promise in improving ADHD symptoms. As long-term studies show that at least 50% of youth are nonadherent with their drug therapy as prescribed over a 1-year period, long-acting formulations (administered once/day) may improve adherence. Comorbid conditions are common in patients with ADHD, but this patient population can be treated effectively with individualized treatment regimens of stimulants, atomoxetine, or bupropion, along with close monitoring.

A clinician’s guide to ADHD treatment options

Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management

A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder

Treatment strategies for ADHD: an evidence-based guide to select optimal treatment

The safety of extended-release drug formulations for the treatment of ADHD

Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants

Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder

Attention-deficit-hyperactivity disorder: an update

[Attention deficit hyperactivity: pharmacotherapy through life]

From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care

Alternative pharmacological strategies for adult ADHD treatment: a systematic review

Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges

Attention Deficit Hyperactivity Disorder in Adults: A Guide for the Primary Care Physician

Treatments for ADHD in Children and Adolescents: A Systematic Review

Are all ADHD medications created equal? Exploring the differences that enable evening dosing

Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Practice Guidelines Development: The APSARD United States Guidelines for the Diagnosis and Treatment of ADHD in Adults

Drivers and Barriers to Tolerable and Effective Treatment for ADHD: The Importance of Treatment Perseverance and Duration of Effect

Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents

Attention-Deficit/Hyperactivity Disorder in Adults

Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.